COX
Cyclooxygenase
Cyclooxygenase (COX), officially known as prostaglandin-endoperoxide synthase (PTGS), is an enzyme that is responsible for formation of important biological mediators called prostanoids, including prostaglandins, prostacyclin and thromboxane. Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain. Drugs, like Aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, exert their effects through inhibition of COX. The main COX inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs).
COX Isoform Specific Products
All Product Categories
-
COX Related Products (1325)
Related Products (1325)
-
Antibodies (6)
-
COX Isoform Comparison
-
Clonixin-13C,d3
0 ImagesCat. No.: HY-121235S1Synonyms: SCH-10304-13C,d3Clonixin-13C,d3 (SCH-10304-13C,d3) is the deuterium and 13C-labeled Clonixin (HY-121235). Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca2+ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain.
-
Rutaecarpine (Standard)
0 ImagesRutaecarpine (Standard) is the analytical standard of Rutaecarpine. This product is intended for research and analytical applications. Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC50 value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).
-
Continentalic acid (Standard)
0 ImagesCat. No.: HY-N6908RCAS No.: 19889-23-7Continentalic acid (Standard) is the analytical standard of Continentalic acid (HY-N6908). This product is intended for research and analytical applications. Continentalic acid is a diterpenoid organic acid. Continentalic acid exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial and antitumor effects. Continentalic acid alleviates oxidative stress, reduces pro-inflammatory cytokine production, inhibits MAPK phosphorylation and neutrophil infiltration, and induces growth inhibition and apoptosis of cancer cells. Continentalic acid can be used in research related to traumatic brain injury, cancer, inflammation and infections.
-
Isoscoparin-7-O-glucoside
0 ImagesCat. No.: HY-N13040CAS No.: 50307-26-1Isoscoparin-7-O-glucoside is a flavonoid compound found in barley leaves. The total phenolic content (TPC) of isoscoparin-7-O-glucoside is positively correlated with COX-2 inhibitory activity, indicating anti-inflammatory activity. Isoscoparin-7-O-glucoside can be used in the study of inflammation.
-
Tenoxicam-d4
0 ImagesCat. No.: HY-W741411CAS No.: 1329834-60-7Synonyms: Ro-12-0068-d4
-
Zidometacin
0 ImagesCat. No.: HY-159634CAS No.: 62851-43-8Zidometacin is a nonsteroidal anti-inflammatory agent. Zidometacin significantly inhibits prostaglandin synthesis with low gastrolesive influence. Zidometacin has antinociceptive and antipyretic activities and shows relatively low ulcerogenicity in rat models. Zidometacin can be used for analgesia and osteoarthritis research.
-
COX-1/2-IN-1
0 ImagesCat. No.: HY-115966CAS No.: 2358849-47-3COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 13.9 ± 3.21 µM and 6.4±0.74 µM, respectively.
-
SIN 14
0 ImagesCat. No.: HY-173518CAS No.: 3064262-80-9SIN 14, a derivative of Sinomenine (HY-15122), is an orally active HO-1 activator (KD = 17.2 μM). SIN 14 binds to the catalytic core domain of HO-1 and induces HO-1 activation in catalysis. SIN 14 significantly increases HO-1 stability. SIN 14 has anti-inflammatory effects and inhibits M1 macrophage polarization while promoting M2 polarization in LPS (Lipopolysaccharides)(HY-D1056)-induced RAW264.7 cells. SIN 14 inhibits inflammatory mediator production (eg: NO, IL-6, IL-1β and CCL2, inhibits production of ROS and down-regulates the expression of COX-2 and iNOS. SIN 14 can inhibit RA-related inflammatory edema in collagen-induced arthritis (ClA) mice.
-
COX-2-IN-31
0 ImagesCat. No.: HY-149270CAS No.: 3039955-76-2
-
Valdecoxib-13C2,15N
0 ImagesCat. No.: HY-W777079CAS No.: 1189428-23-6Synonyms: SC 65872-13C2,15NValdecoxib-13C2,15N (SC 65872-13C2,15N) is the 13C- and 15N-labeled Valdecoxib (HY-15762). Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
-
Anti-inflammatory agent 111
0 ImagesCat. No.: HY-181155Anti-inflammatory agent 111 is a potent anti-inflammatory agent. Anti-inflammatory agent 111 reduces Lipopolysaccharides (LPS) (HY-D1056)-induced i-NOS and COX-2 protein expression, decreases nitric oxide, IL-6, and TNF-α production. Anti-inflammatory agent 111 maintains normal cell viability at bioactive concentrations.Anti-inflammatory agent 111 can be used for the research of inflammation-related disorders.
-
Indobufen-d5
0 ImagesCat. No.: HY-18763SSynonyms: Ibustrin-d5Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
-
Ginsenoside Rg5 (Standard)
0 ImagesCat. No.: HY-N0908RCAS No.: 186763-78-0Ginsenoside Rg5 (Standard) is the analytical standard of Ginsenoside Rg5. This product is intended for research and analytical applications. Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.
-
Ephemeranthol A
0 ImagesCat. No.: HY-N17888CAS No.: 135545-86-7Ephemeranthol A is a phenanthrene compound with anticancer and anti-inflammatory activities. Ephemeranthol A exerts significant anti-inflammatory effects in macrophages by inhibiting the NF-κB and MAPK signaling pathways. Ephemeranthol A induces apoptosis and inhibits metastasis of lung cancer cells by suppressing the FAK/Akt signaling and EMT processes. Ephemeranthol A can be used for the research of acute and chronic inflammatory diseases and non-small cell lung cancer.
-
Mofebutazone sodium
0 ImagesCat. No.: HY-W009640ACAS No.: 41468-34-2Mofebutazone sodium is a pyrazolidinedione non-steroidal anti-inflammatory agent (NSAID). Mofebutazone sodium exhibits weak COX inhibition, no effect on LOX, and slightly suppresses the percentage of leukocyte phagocytosis in vitro. Mofebutazone sodium can be used in research related to soft tissue rheumatism.
-
5α-Epoxyalantolactone
0 ImagesCat. No.: HY-N21980CAS No.: 65563-75-95α-Epoxyalantolactone is an orally active, blood-brain barrier-permeable ANXA2 inhibitor. 5α-Epoxyalantolactone binds to ANXA2, blocks the formation of ANXA2-S100A10 heterotetramers, inhibits the membrane trafficking of E-cadherin, and prevents metastasis of breast cancer cells as well as proliferation of breast cancer stem cells. 5α-Epoxyalantolactone improves cognitive and memory impairments by inhibiting the iNOS/COX-2/NF-κB pathway and reducing the activity of cerebral AChE. 5α-Epoxyalantolactone can be used in studies related to Alzheimer's disease and triple-negative breast cancer.
